135
Views
0
CrossRef citations to date
0
Altmetric
Article

A comparative in vitro microbiological evaluation of generic meropenem compounds against the innovator compound

, MBBCh, MMed(Wits), FCPath(Micro), , NDMedTech(Clin Path and Micro) NHDMedTech, , NDMedTech (Micro), , NDMedTech (Micro) & , NDMedTech (Clin Path and Micro)
Pages 73-77 | Received 05 Apr 2011, Accepted 05 Jun 2011, Published online: 15 Jul 2015

References

  • Bamford C, Badenhorst L, Duse A et al. Antimicrobial susceptibility patterns of selected invasive pathogens from public sector hospitals in South Africa. South Afr J Epidemiol and Infect 2007; 24: 28–30.
  • Methods for determining bactericidal activity of antimicrobial agents: approved guideline. Pennsylvania: Clinical and Laboratory Standards Institute; 1999.
  • Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria That Grow Aerobically; Approved Standard – 7th Edition. Pennsylvania: Clinical and Laboratory Standards Institute; 2006
  • Performance standards for antimicrobial susceptibility testing: 20th Informational Supplement, M100-S20. Pennsylvania: Clinical and Laboratory Standards Institute; 2010
  • Jorgensen JH. Selection criteria for an antimicrobial susceptibility testing system. J Clin Microbio1, 1993; 31:2841–2844.
  • Kumar A, Haery C, Paladugu B et al. The duration of hypotension before the initiation of antibiotic treatment is a critical determinant of survival in a murine model of Escherichia coil septic shock: association with serum lactate and inflammatory cytokine levels. J Infect Dis, 2006; 193; 251–258.
  • Nicolau DR Pharmacokinetic and pharmacodynamic properties of meropenem. Clin Infect Dis. 2008; 47 Suppl 1:S32–40.
  • Rhomberg PR, Jones RN. Summary trends for the meropenem yearly susceptibility test information collection program: a 10-year experience in the United States (1999-2008). Diagn Microbiol Infect Dis, 2009; 65:414–426.
  • Rodriguez CA, Agudelo M, Zuluaga AF, Vesga O. In vitro and in vivo comparison of the anti-staphylococcalefficacy of generic products and the innovator of oxacillin. BMC Infect Dis. 2010; 10: 153.
  • Vesga O, Agudelo M, Salazar BE et al. Generic vancomycin products fail in vivo despite being pharmaceuti-cal equivalents of the innovator. Antimicrob Agents Chemother, 2010;54(8):3271–9.
  • Zuluaga AF, Agudelo M, Cardetio JJ et al. Determination of therapeutic equivalence of generic products of gentamicin in the neutropenic mouse thigh infection model. PLoS One. 2010; 20;5(5):e10744